Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Pyoderma Gangrenosum. According to GlobalData, Phase II drugs for Pyoderma Gangrenosum does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Spesolimab LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Spesolimab overview
Spesolimab (Spevigo, Sanlizo) is an interleukin-36 receptor antagonist. It is formulated as injection solution and concentration for solution for the intravenous and subcutaneous route of administration. Spevigo is indicated for the treatment of generalized pustular psoriasis flares in adults.
Spesolimab (BI-655130) is under development for the treatment of moderate or severe hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, generalized pustular psoriasis (GPP) flares, plaque psoriasis, Netherton Syndrome and unspecified indication. It is administered through intravenous and subcutaneous routes as a solution. The drug candidate acts by targeting interleukin-36 receptor.
It was under development for atopic dermatitis through subcutaneous route, ulcerative colitis, Crohn's disease and palmoplantar pustulosis.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.
For a complete picture of Spesolimab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
